Rigel Pharmaceuticals, Inc. today announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) who had failed at least one prior treatment. The published data demonstrate that fostamatinib, an oral spleen tyrosine kinase (SYK)…
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- ໃນມື້ນີ້ໄດ້ປະກາດການພິມເຜີຍແຜ່ຂໍ້ມູນໃນ American Journal of Hematology ຈາກປ້າຍເປີດ, multicenter, ໄລຍະ 2 ການສຶກສາທາງດ້ານການຊ່ວຍຂອງ fostaatinib ໃນຜູ້ໃຫຍ່ທີ່ມີພູມຕ້ານທານທີ່ອົບອຸ່ນ autoimmune hemolytic anemia (wAIHA) ຜູ້ທີ່ໄດ້ລົ້ມເຫລວຢ່າງຫນ້ອຍຫນຶ່ງການປິ່ນປົວກ່ອນ.
- The published data demonstrate that fostamatinib, an oral spleen tyrosine kinase (SYK)….
- ການສະໝັກໃຊ້ແມ່ນບໍ່ເສຍຄ່າ.